Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis

BMJ Open

Volumn 6, Issue 6, 2016, Pages

  Hinds, David R ^a   DiSantostefano, Rachael L ^a   Le, Hoa V ^a,b   Pascoe, Steven ^a  

^a GLAXOSMITHKLINE   (United States)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

Chronic obstructive pulmonary disease; Cluster analysis; Eosinophil; Inhaled corticosteroid; Long acting 2 agonist

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL; UMECLIDINIUM; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; CORTICOSTEROID; FLUTICASONE FUROATE;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG RESPONSE; DRY POWDER INHALER; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CYTOLOGY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ANDROSTADIENES; BENZYL ALCOHOLS; CHLOROBENZENES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TREATMENT OUTCOME; UNITED STATES;

EID: 84974667187     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010099     Document Type: Article

References (30)

1. De Soyza A, Calverley PM. Large trials, new knowledge: the changing face of COPD management. Eur Respir J 2015; 45: 1692-703.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD: 2015 update to guidelines. http://www.goldcopd.org/.(accessed 23 Mar 2015
3. Aaron SD. Management and prevention of exacerbations of COPD. BMJ 2014; 349: g5237.
4. Agarwal R, Aggarwal AN, Gupta D, et al. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010; 137: 318-25.
5. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641-7.
6. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-23.
7. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102: 1099-108.
8. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 39-47.
9. Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012; 106: 257-68.
10. Szafranski WW, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
11. DeCoster DA, Jones M. Tailoring of corticosteroids in COPD management. Curr Respir Care Rep 2014; 3: 121-32.
12. Weatherall M, Shirtcliffe P, Travers J, et al. Use of cluster analysis to define COPD phenotypes. Eur Respir J 2010; 36: 472-4.
13. DiSantostefano RL, Li H, Rubin DB, et al. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open 2013; 3: e001838.
14. Breiman L. Classification and regression trees. New York, NY, USA: Chapman and Hall, 1983.
15. Green RH, Pavord I. Stability of inflammatory phenotypes in asthma. Thorax 2012; 67: 665-7.
16. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
17. Bathoorn E, Liesker JJ, Postma DS, et al. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. COPD 2008; 5: 282-90.
18. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-Term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356: 1480-5.
19. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-8.
20. Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med 2013; 7: 33-42.
21. Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012; 7: 283-9.
22. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006; 27: 964-71.
23. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-42.
24. Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol 2015; 135: 877-83.e1.
25. Fleming L, Wilson N, Regamey N, et al. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax 2012; 67: 193-8.
26. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-21.
27. Eltboli O, Mistry V, Barker B, et al. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology 2015; 20: 667-70.
28. Hillas G, Loukides S, Kostikas K, et al. Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect?. Curr Med Chem 2009; 16: 2824-38.
29. Gibson PG. Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD. Eur Respir J 2013; 42: 891-2.
30. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44: 1697-700.